Literature DB >> 21796096

HIV-2 Infection Surveillance--United States, 1987-2009.

.   

Abstract

Human immunodeficiency virus (HIV) is categorized into two types, HIV-1 and HIV-2. Worldwide, most HIV infections are HIV-1, whereas HIV-2 largely has been confined to persons in or from West Africa. HIV-1 and HIV-2 have the same routes of transmission, and both can cause acquired immunodeficiency syndrome (AIDS); however, HIV-2 infections should be differentiated from HIV-1 infections because they are less likely to cause AIDS and their clinical management differs. CDC's current surveillance case definition for HIV infection applies to both variants of HIV but lacks criteria for differentiating between HIV-1 and HIV-2. To enumerate and describe HIV-2 cases reported in the United States, a working case definition was developed. During 1988--June 2010, a total of 242 HIV-2 cases were reported to CDC. Of these, 166 met the working definition. These HIV-2 cases were concentrated in the Northeast (66%, including 46% in New York City) and occurred primarily among persons born in West Africa (81%). Ninety-seven of the HIV-2 cases also had a positive HIV-1 immunoblot antibody test result (e.g., Western blot). Immunoblot antibody tests currently used to confirm HIV reactive screening tests do not contain reagents specific to HIV-2 and thus are not reliable for identification of HIV-2 infections. Additional testing specific to HIV-2 should be considered if HIV-1 test results are atypical or inconsistent with clinical findings, especially for persons from West Africa. If an HIV case is reported to the health department but subsequently identified as HIV-2, health-care providers should update the case report to reflect the correct type.

Entities:  

Mesh:

Year:  2011        PMID: 21796096

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  20 in total

1.  The global dimensions of public health preparedness and implications for US action.

Authors:  Melinda Moore
Journal:  Am J Public Health       Date:  2012-04-19       Impact factor: 9.308

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

3.  HIV testing updates and challenges: when regulatory caution and public health imperatives collide.

Authors:  Bernard M Branson
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

4.  Rapid detection of human immunodeficiency virus types 1 and 2 by use of an improved piezoelectric biosensor.

Authors:  Marco Bisoffi; Virginia Severns; Darren W Branch; Thayne L Edwards; Richard S Larson
Journal:  J Clin Microbiol       Date:  2013-03-20       Impact factor: 5.948

5.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

6.  Trends in Women With an HIV Diagnosis at Delivery Hospitalization in the United States, 2006-2014.

Authors:  Maria Vyshnya Aslam; Kwame Owusu-Edusei; Steven R Nesheim; Kristen Mahle Gray; Margaret A Lampe; Patricia Marie Dietz
Journal:  Public Health Rep       Date:  2020-07-10       Impact factor: 2.792

7.  Use of rapid HIV assays as supplemental tests in specimens with repeatedly reactive screening immunoassay results not confirmed by HIV-1 Western blot.

Authors:  Laura G Wesolowski; Kevin P Delaney; William A Meyer; Amy J Blatt; Berry Bennett; Pollyanna Chavez; Timothy C Granade; Michele Owen
Journal:  J Clin Virol       Date:  2013-07-06       Impact factor: 3.168

8.  Detection and differentiation of HIV-2 using the point-of-care Alere q HIV-1/2 Detect nucleic acid test.

Authors:  Ming Chang; Katrin Steinmetzer; Dana N Raugi; Robert A Smith; Selly Ba; Fatima Sall; Moussa Seydi; Alassane Niang; ElHadji Ibrahima Sall; Ousseynou Cisse; Katja Rödel; Robert W Coombs; Geoffrey S Gottlieb
Journal:  J Clin Virol       Date:  2017-10-24       Impact factor: 3.168

Review 9.  Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

10.  Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform.

Authors:  Ming Chang; Geoffrey S Gottlieb; Joan A Dragavon; Stephen L Cherne; Donna L Kenney; Stephen E Hawes; Robert A Smith; Nancy B Kiviat; Papa Salif Sow; Robert W Coombs
Journal:  J Clin Virol       Date:  2012-07-24       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.